Comorbidities and systemic features
The multisystem reality — dysautonomia and POTS, MCAS, GI, pain, fatigue, and the comorbidity structure the community named before the literature did.
The "trifecta" — hEDS, POTS/dysautonomia, and MCAS co-clustering
community signalcommunity signalstrata convergePatient communities converged on the hEDS–POTS–MCAS triad years before it appeared in clinical reviews. Registry data now supports the clustering: in the Global Registry survey (n=505), POTS and mast cell activation syndrome were among the alternative diagnoses participants most endorsed as accurate. The triad is community-coined and increasingly clinically studied; the mechanism remains unexplained.
The 2017 classification moved EDS from a skin-and-joints frame to an explicitly multisystem one — systemic manifestations entered the hEDS criteria themselves, and companion papers covered GI, cardiovascular-autonomic, pain, and psychiatric comorbidity. This codified what patient communities had long reported.
hEDS patients average ten alternative diagnoses before confirmation
establishedfindingstrata convergeThe Global Registry survey (n=505, clinically confirmed hEDS) found a mean of 10.45 alternative diagnoses — most commonly anxiety, depression, and migraine — with functional neurological disorder and multiple sclerosis among the most-rejected labels. Post-diagnosis, participants most endorsed POTS, cervical instability, and MCAS as accurate.
Craniocervical instability and tethered cord — the contested frontier
contestedfindingstrata convergeCraniocervical instability and tethered-cord claims circulate strongly in community venues and some surgical case series, and CCI was among the most-endorsed diagnoses in the registry survey. Controlled evidence remains limited and surgical intervention carries real risk; this index marks the area contested rather than dismissing it.
The 2017 series and subsequent cohort work document gastrointestinal dysmotility (reflux, gastroparesis, constipation) and autonomic dysfunction (orthostatic intolerance, POTS) as leading comorbidity domains in hEDS/HSD. The German 2025 cohort shows musculoskeletal pain and joint instability as the dominant presenting manifestations.